NEW YORK, Aug. 15, 2023 /PRNewswire/ — Technavio, a leading provider of industry news and insights, is pleased to announce its latest report on the Liquid Biopsy Market. The report highlights the estimated growth and forecast for the market between 2022 and 2027, predicting an increase in market size of USD 1.74 Billion and a rise at a CAGR of 18.77%.
The liquid biopsy market is propelled by the increasing cancer prevalence, especially among the aging population, and the adoption of non-invasive methods for cancer detection. Sizeable investments in advanced DNA testing, such as CTC and ctDNA analysis, are fostering innovation. The market’s potential for personalized medicine and targeted therapies, along with its ability to provide genetic insights, further contributes to its growth. These drivers collectively position the liquid biopsy market for innovative cancer detection and management.
The liquid biopsy market is being shaped by trends such as increased funding, personalized medicine, non-invasive diagnostics, technological advancements, and the impact of the COVID-19 pandemic. These trends are driving innovation and expanding the utility of liquid biopsy in revolutionizing cancer detection, monitoring, and treatment strategies.
YoY growth 2022-2023(%)
North America, Europe, Asia, and Rest of World (ROW)
The report provides comprehensive insights into the market, and it is segmented by technology – CTC and ctDNA and Exosome and RNA and geography – North America, Europe, Asia, and Rest of World (ROW)This segmentation provides a comprehensive view of the market, encompassing diverse communication solutions and regions. Furthermore, it examines key trends shaping the companies landscape and identifies potential challenges faced by market players. To get insights into the key trends, download the sample report here!
The major Liquid Biopsy Market companies include AccuraGen Holdings, Adaptive Biotechnologies Corp., ANGLE Plc, Bio Rad Laboratories Inc., Biocept Inc., CellMax Inc., Epigenomics AG, F. Hoffmann La Roche Ltd., GeneFirst Ltd., Guardant Health Inc., HansaBioMed Life Sciences Ltd., Illumina Inc., MDNA Lfe Sciences Inc., MDxHealth Group, NeoGenomics Laboratories Inc., QIAGEN NV, Rarecells Inc., SAGA Diagnostics AB, Siemens Healthcare GmbH and Thermo Fisher Scientific Inc.
These companies are actively implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product launches, to enhance their presence and competitiveness in Liquid Biopsy Market.
The Global Liquid Biopsy market is driven by the escalating prevalence of cancer and the adoption of non-invasive testing methods. While significant investments and funding support advancements, challenges linked to limited reimbursement persist. North America is set to be a key growth contributor, fueled by increasing cancer cases, advanced diagnostics, and anti-cancer drug development. Circulating Tumor Cells (CTC) and circulating tumor DNA (ctDNA) segments are anticipated to be major revenue drivers, with ctDNA’s sensitivity and dynamic monitoring capabilities standing out. Despite challenges, the liquid biopsy market holds promise for innovative cancer detection and management in the future.
Technavio provides a report that includes competitive intelligence, highlighting major players’ key developments and growth strategies, enabling stakeholders to make informed decisions and stay competitive in the market. To buy the complete report on Liquid Biopsy Market, click here.
Below, are other reports you might be interested with:
Breast Cancer Liquid Biopsy Testing Devices Market: The breast cancer liquid biopsy testing devices market share is expected to increase to USD 730.4 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 23.58%. This report covers pathology instruments market segmentation by type (CTCs and circulating nucleic acids and extracellular vesicles) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Lung Cancer Liquid Biopsy Market: The lung cancer liquid biopsy market size will record an incremental growth of $ 292.89 Million and a CAGR of 16% during 2020-2024. The report covers segmentation by product (CTCs and ctDNA and Exosomes and RNA) and geography (North America, Europe, Asia, and ROW)
Technavio is a trusted source for industry news and insights that help businesses stay ahead in today’s competitive landscape. With a team of experienced analysts and researchers, we continuously scrutinize and evaluate the dynamic landscape of markets across the globe. Our comprehensive coverage, meticulous research methodologies, and pragmatic industry expertise have earned us the trust and reliance of a vast clientele, including over 100 esteemed Fortune 500 organizations.
View original content to download multimedia:https://www.prnewswire.com/news-releases/liquid-biopsy-market-is-to-grow-at-a-cagr-of-18-77-between-2023-and-2027–the-rising-prevalence-of-cancer-drives-the-market-301899649.html